SBIR-STTR Award

Microneedle Delivery of Zanamivir for Treatment of Influenza
Award last edited on: 11/17/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$5,494,326
Award Phase
2
Solicitation Topic Code
855
Principal Investigator
Elke Lipka

Company Information

TSRL Inc (AKA: Therapeutic Systems Research Laboratories)

540 Avis Drive Suite A
Ann Arbor, MI 48108
   (734) 663-4233
   info@tsrlinc.com
   www.tsrlinc.com
Location: Single
Congr. District: 12
County: Washtenaw

Phase I

Contract Number: 1R43AI129122-01A1
Start Date: 3/1/2017    Completed: 2/28/2019
Phase I year
2017
Phase I Amount
$287,765
Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is

Public Health Relevance Statement:
Project Narrative TSRL and its collaborator F6 Pharma is developing a novel transdermal delivery product of zanamivir for the treatment if the flu. The proposed research will establish the proof-of-concept that effective treatment of the flu can be achieved with a patch. Completion of the work in this proposal would render the candidate ready for full preclinical development.

Project Terms:
absorption; abstracting; Adamantane; Address; Adoption; Adverse effects; Animals; anti-influenza; anti-influenza drug; Antiviral Agents; aqueous; Asthma; Biological Availability; biothreat; Birds; Blood Circulation; Breathing; Caliber; Categories; Cessation of life; Contract Services; Correlation Studies; Data; Deglutition; design; Development; Devices; Diffuse; Dose; driving force; Drug Kinetics; economic impact; effective therapy; efficacy study; efficacy testing; Elderly; Employee Strikes; Ensure; Epidemic; Excipients; Family; Family suidae; flu; Formulation; Funding; Future; Grant; Human; Hydrogels; In Vitro; in vivo; Influenza; influenza epidemic; influenza outbreak; influenzavirus; Inhalators; Investigational Drugs; Investigational New Drug Application; Killings; Length; Mammals; Manufactured Supplies; Marketing; Medical; Methods; mortality; Mus; National Institute of Allergy and Infectious Disease; Needles; Neuraminidase inhibitor; novel; Oral; Orthomyxoviridae; Oryctolagus cuniculus; Oseltamivir; Pain; Painless; pandemic disease; Patients; Penetration; Pharmaceutical Preparations; Pharmacotherapy; Phase; Physicians; Population; pre-clinical; preclinical development; preclinical efficacy; preclinical safety; preconditioning; prevent; Preventive measure; Production; Property; prototype; Puncture procedure; Regimen; Research; research clinical testing; Research Design; Resistance; resistant strain; respiratory; Respiratory System; Risk; RNA Viruses; Route; Safety; screening; seasonal influenza; Skin; skin barrier; skin irritation; Sodium Chloride; Solubility; Solvents; Syringes; System; Testing; Therapeutic; Toxicology; Universities; Utah; Vaccination; Vaccines; Viral; Virus; Visit; Work; zanamivir

Phase II

Contract Number: 5R43AI129122-02
Start Date: 3/1/2017    Completed: 3/31/2019
Phase II year
2018
(last award dollars: 2023)
Phase II Amount
$5,206,561

Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is

Public Health Relevance Statement:
Project Narrative TSRL and its collaborator F6 Pharma is developing a novel transdermal delivery product of zanamivir for the treatment if the flu. The proposed research will establish the proof-of-concept that effective treatment of the flu can be achieved with a patch. Completion of the work in this proposal would render the candidate ready for full preclinical development.

Project Terms:
absorption; Adamantane; Address; Adoption; Adverse effects; Animals; anti-influenza; anti-influenza drug; Antiviral Agents; aqueous; Asthma; Biological Availability; biothreat; Birds; Blood Circulation; Caliber; Categories; Cessation of life; Contract Services; Correlation Studies; Crystallization; Data; Deglutition; design; Development; Devices; Diffuse; Dose; driving force; Drug Kinetics; economic impact; effective therapy; efficacy study; efficacy testing; Elderly; Ensure; Epidemic; Excipients; Family; Family suidae; flu; Formulation; Funding; Future; Grant; Human; Hydrogels; In Vitro; in vivo; Influenza; influenza epidemic; influenza outbreak; influenzavirus; Inhalation; Inhalators; Investigational Drugs; Investigational New Drug Application; Length; Mammals; Manufactured Supplies; Medical; Methods; mortality; Mus; National Institute of Allergy and Infectious Disease; Needles; Neuraminidase inhibitor; novel; Oral; Orthomyxoviridae; Oryctolagus cuniculus; Oseltamivir; pain patient; Painless; pandemic disease; Pathogenicity; Patients; Penetration; Pharmaceutical Preparations; Pharmacotherapy; Phase; Physicians; Population; pre-clinical; preclinical development; preclinical efficacy; preclinical safety; prevent; Preventive measure; Production; Property; prototype; Puncture procedure; Regimen; Research; research clinical testing; Research Design; Resistance; resistant strain; respiratory; Respiratory System; Risk; RNA Viruses; Route; Safety; screening; seasonal influenza; Skin; skin barrier; skin irritation; Sodium Chloride; Solubility; Solvents; Syringes; System; Testing; Therapeutic; Time; Toxicology; Universities; Utah; Vaccination; Vaccines; Viral; Virus; Visit; Work; zanamivir